Abstract
Objective: A subgroup of patients with Tourette's disorder (TD) has symptoms refractory to haloperidol, a standard therapeutic drug for TD.Methods: We report on three cases of pediatric and adolescent patients who were treated with paliperidone extended release.Results: In two cases, TD symptoms were remarkably improved by switching from haloperidol to paliperidone extended release, and in another case, paliperidone extended release showed significant efficacy in treating TD symptoms as the first-line drug. In all cases, no significant adverse side effects were detected.Conclusion: Paliperidone extended release may be a strong candidate for the treatment of pediatric and adolescent patients with TD.
| Original language | English |
|---|---|
| Article number | 13 |
| Journal | Annals of General Psychiatry |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 02-05-2014 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Psychiatry and Mental health
Fingerprint
Dive into the research topics of 'Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver